ERBB2 and neoplasm: A preclinical study showed that afatinib in combination with mammalian TOR (mTOR) inhibitor rapamycin was the most effective way to inhibit the tumor growth in HER2 YVMA-mutant transgenic NSCLC mice when compared to trastuzumab and/or rapamycin treatment.